<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36977164</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2414-6366</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Tropical medicine and infectious disease</Title><ISOAbbreviation>Trop Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for <i>Helicobacter pylori</i> Infections.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">163</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/tropicalmed8030163</ELocationID><Abstract><AbstractText><i>Helicobacter pylori</i> infects approximately 50% of the world's population and is considered the major etiological agent of severe gastric diseases, such as peptic ulcers and gastric carcinoma. Increasing resistance to standard antibiotics has now led to an ever-decreasing efficacy of eradication therapies and the development of novel and improved regimens for treatment is urgently required. Substantial progress has been made over the past few years in the identification of molecular mechanisms which are conducive to resistant phenotypes as well as for efficient strategies to counteract strain resistance and to avoid the use of ineffective antibiotics. These involve molecular testing methods, improved salvage therapies, and the discovery of novel and potent antimicrobial compounds. High rates of prevalence and gastric cancer are currently observed in Asian countries, including Japan, China, Korea, and Taiwan, where concomitantly intensive research efforts were initiated to explore advanced eradication regimens aimed at reducing the risk of gastric cancer. In this review, we present an overview of the known molecular mechanisms of antibiotic resistance and discuss recent intervention strategies for <i>H. pylori</i> diseases, with a view of the research progress in Asian countries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Srisuphanunt</LastName><ForeName>Mayuna</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7421-4410</Identifier><AffiliationInfo><Affiliation>Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Excellent Center for Dengue and Community Public Health, School of Public Health, Walailak University, Nakhon Si Thammarat 80160, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilairatana</LastName><ForeName>Polrat</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2730-7788</Identifier><AffiliationInfo><Affiliation>Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kooltheat</LastName><ForeName>Nateelak</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-7623-854X</Identifier><AffiliationInfo><Affiliation>Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology and Transfusion Science Research Center, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duangchan</LastName><ForeName>Thitinat</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7404-6664</Identifier><AffiliationInfo><Affiliation>Department of Medical Technology, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology and Transfusion Science Research Center, School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katzenmeier</LastName><ForeName>Gerd</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Akkhraratchakumari Veterinary College, Walailak University, Nakhon Si Thammarat 80160, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>Joan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Fisheries and Wildlife, Michigan State University, East Lansing, MI 48823, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>WU-IRG-64-077</GrantID><Agency>Walailak University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Trop Med Infect Dis</MedlineTA><NlmUniqueID>101709042</NlmUniqueID><ISSNLinking>2414-6366</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Helicobacter pylori</Keyword><Keyword MajorTopicYN="N">antibiotic resistance</Keyword><Keyword MajorTopicYN="N">drug development</Keyword><Keyword MajorTopicYN="N">salvage therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>15</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36977164</ArticleId><ArticleId IdType="pmc">PMC10057134</ArticleId><ArticleId IdType="doi">10.3390/tropicalmed8030163</ArticleId><ArticleId IdType="pii">tropicalmed8030163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hooi J.K.Y., Lai W.Y., Ng W.K., Suen M.M.Y., Underwood F.E., Tanyingoh D., Malfertheiner P., Graham D.Y., Wong V.W.S., Wu J.C.Y., et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017;153:420&#x2013;429. doi: 10.1053/j.gastro.2017.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.04.022</ArticleId><ArticleId IdType="pubmed">28456631</ArticleId></ArticleIdList></Reference><Reference><Citation>Suerbaum S., Michetti P. Helicobacter pylori infection. N. Engl. J. Med. 2002;347:1175&#x2013;1186. doi: 10.1056/NEJMra020542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra020542</ArticleId><ArticleId IdType="pubmed">12374879</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001;345:784&#x2013;789. doi: 10.1056/NEJMoa001999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa001999</ArticleId><ArticleId IdType="pubmed">11556297</ArticleId></ArticleIdList></Reference><Reference><Citation>Roesler B.M., Rabelo-Gon&#xe7;alves E.M., Zeitune J.M. Virulence factors of Helicobacter pylori: A review. Clin. Med. Insights Gastroenterol. 2014;7:9&#x2013;17. doi: 10.4137/CGast.S13760.</Citation><ArticleIdList><ArticleId IdType="doi">10.4137/CGast.S13760</ArticleId><ArticleId IdType="pmc">PMC4019226</ArticleId><ArticleId IdType="pubmed">24833944</ArticleId></ArticleIdList></Reference><Reference><Citation>Salih B.A. Helicobacter pylori infection in developing countries: The burden for how long? Saudi J. Gastroenterol. 2009;15:201&#x2013;207. doi: 10.4103/1319-3767.54743.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1319-3767.54743</ArticleId><ArticleId IdType="pmc">PMC2841423</ArticleId><ArticleId IdType="pubmed">19636185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafar S., Jalil A., Soheila N., Sirous S. Prevalence of helicobacter pylori infection in children, a population-based cross-sectional study in west iran. Iran J. Pediatr. 2013;23:13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3574986</ArticleId><ArticleId IdType="pubmed">23550042</ArticleId></ArticleIdList></Reference><Reference><Citation>Quach D.T., Vilaichone R.K., Vu K.V., Yamaoka Y., Sugano K., Mahachai V. Helicobacter pylori infection and related gastrointestinal diseases in southeast Asian countries: An expert opinion survey. Asian Pac. J. Cancer Prev. 2018;19:3565&#x2013;3569. doi: 10.31557/APJCP.2018.19.12.3565.</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/APJCP.2018.19.12.3565</ArticleId><ArticleId IdType="pmc">PMC6428556</ArticleId><ArticleId IdType="pubmed">30583684</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani M., Ebrahimtabar F., Zamani V., Miller W.H., Alizadeh-Navaei R., Shokri-Shirvani J., Derakhshan M.H. Systematic review with meta-analysis: The worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol. Ther. 2018;47:868&#x2013;876. doi: 10.1111/apt.14561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.14561</ArticleId><ArticleId IdType="pubmed">29430669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Zhu Y., Lu N.H. Recent progress in Helicobacter pylori treatment. Chin. Med. J. 2020;133:335&#x2013;343. doi: 10.1097/CM9.0000000000000618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000000618</ArticleId><ArticleId IdType="pmc">PMC7004604</ArticleId><ArticleId IdType="pubmed">31929363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacconelli E., Carrara E., Savoldi A., Harbarth S., Mendelson M., Monnet D.L., Pulcini C., Kahlmeter G., Kluytmans J., Carmeli Y., et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018;18:318&#x2013;327. doi: 10.1016/S1473-3099(17)30753-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(17)30753-3</ArticleId><ArticleId IdType="pubmed">29276051</ArticleId></ArticleIdList></Reference><Reference><Citation>Malfertheiner P., Megraud F., O&#x2019;Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6&#x2013;30. doi: 10.1136/gutjnl-2016-312288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2016-312288</ArticleId><ArticleId IdType="pubmed">27707777</ArticleId></ArticleIdList></Reference><Reference><Citation>Long X., Chen Q., Yu L., Liang X., Liu W., Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter. 2018;23:e12485. doi: 10.1111/hel.12485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12485</ArticleId><ArticleId IdType="pubmed">29696736</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. World Health Organization; Geneva, Switzerland: 2017.</Citation></Reference><Reference><Citation>Kim S.Y., Chung J.W. Best Helicobacter pylori eradication strategy in the era of antibiotic resistance. Antibiotics. 2020;9:436. doi: 10.3390/antibiotics9080436.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics9080436</ArticleId><ArticleId IdType="pmc">PMC7459868</ArticleId><ArticleId IdType="pubmed">32717826</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo Y.T., Liou J.M., El-Omar E.M., Wu J.Y., Leow A.H.R., Goh K.L., Das R., Lu H., Lin J.T., Tu Y.K., et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2017;2:707&#x2013;715. doi: 10.1016/S2468-1253(17)30219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(17)30219-4</ArticleId><ArticleId IdType="pubmed">28781119</ArticleId></ArticleIdList></Reference><Reference><Citation>Tshibangu-Kabamba E., Yamaoka Y. Helicobacter pylori infection and antibiotic resistance&#x2014;From biology to clinical implications. Nat. Rev. Gastroenterol. Hepatol. 2021;18:613&#x2013;629. doi: 10.1038/s41575-021-00449-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-021-00449-x</ArticleId><ArticleId IdType="pubmed">34002081</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan Z.A., Siddiqui M.F., Park S. Current and emerging methods of antibiotic susceptibility testing. Diagnostics. 2019;9:49. doi: 10.3390/diagnostics9020049.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics9020049</ArticleId><ArticleId IdType="pmc">PMC6627445</ArticleId><ArticleId IdType="pubmed">31058811</ArticleId></ArticleIdList></Reference><Reference><Citation>European Committee on Antimicrobial Susceptibility Testing . Breakpoint Tables for Interpretation of MICs and Zone Diameters Version 11.0. European Committee on Antimicrobial Susceptibility Testing; Basel, Switzerland: 2021.</Citation></Reference><Reference><Citation>De Francesco V., Giorgio F., Hassan C., Manes G., Vannella L., Panella C., Ierardi E., Zullo A. Worldwide H. pylori antibiotic resistance: A systematic review. J. Gastrointestin. Liver. Dis. 2010;19:409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">21188333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghotaslou R., Leylabadlo H.E., Asl Y.M. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World J. Methodol. 2015;5:164&#x2013;174. doi: 10.5662/wjm.v5.i3.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.5662/wjm.v5.i3.164</ArticleId><ArticleId IdType="pmc">PMC4572030</ArticleId><ArticleId IdType="pubmed">26413490</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilaichone R.K., Quach D.T., Yamaoka Y., Sugano K., Mahachai V. Prevalence and pattern of antibiotic resistant strains of Helicobacter pylori infection in ASEAN. Asian Pac. J. Cancer Prev. 2018;19:1411&#x2013;1413. doi: 10.22034/apjcp.2018.19.5.1411.</Citation><ArticleIdList><ArticleId IdType="doi">10.22034/apjcp.2018.19.5.1411</ArticleId><ArticleId IdType="pmc">PMC6031816</ArticleId><ArticleId IdType="pubmed">29802708</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoosanglertwijit R., Kamrat N., Werawatganon D., Chatsuwan T., Chaithongrat S., Rerknimitr R. Real-world data of Helicobacter pylori prevalence, eradication regimens, and antibiotic resistance in Thailand, 2013&#x2013;2018. JGH Open. 2020;4:49&#x2013;53. doi: 10.1002/jgh3.12208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgh3.12208</ArticleId><ArticleId IdType="pmc">PMC7008154</ArticleId><ArticleId IdType="pubmed">32055697</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Zhang M., Lu B., Dai J. Helicobacter pylori and antibiotic resistance, a continuing and intractable problem. Helicobacter. 2016;21:349&#x2013;363. doi: 10.1111/hel.12299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12299</ArticleId><ArticleId IdType="pubmed">26822340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschl A.M., Rotter M.L. Amoxicillin for the treatment of Helicobacter pylori infection. J. Gastroenterol. 1996;31((Suppl. S9)):44&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8959518</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishizawa T., Suzuki H., Tsugawa H., Muraoka H., Matsuzaki J., Hirata K., Ikeda F., Takahashi M., Hibi T. Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication. Antimicrob. Agents Chemother. 2013;57:1106. doi: 10.1128/AAC.02497-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02497-12</ArticleId><ArticleId IdType="pmc">PMC3101459</ArticleId><ArticleId IdType="pubmed">21486961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M.-J., Wu M.-S., Chen C.-C., Chen C.-C., Fang Y.-J., Bair M.-J., Chang C.-Y., Lee J.-Y., Hsu W.-F., Luo J.-C., et al. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: Analysis of five randomized trials. J. Antimicrob. Chemother. 2017;72:3481&#x2013;3489. doi: 10.1093/jac/dkx320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx320</ArticleId><ArticleId IdType="pubmed">28961996</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui R., Song Z., Suo B., Tian X., Xue Y., Meng L., Niu Z., Jin Z., Zhang H., Zhou L. Correlation analysis among genotype resistance, phenotype resistance and eradication effect of Helicobacter pylori. Infect. Drug Resist. 2021;14:1747&#x2013;1756. doi: 10.2147/IDR.S305996.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S305996</ArticleId><ArticleId IdType="pmc">PMC8127322</ArticleId><ArticleId IdType="pubmed">34012273</ArticleId></ArticleIdList></Reference><Reference><Citation>Albasha A.M., Elnosh M.M., Osman E.H., Zeinalabdin D.M., Fadl A.A.M., Ali M.A., Altayb H.N. Helicobacter pylori 23S rRNA gene A2142G, A2143G, T2182C, and C2195T mutations associated with clarithromycin resistance detected in Sudanese patients. BMC Microbiol. 2021;21:38. doi: 10.1186/s12866-021-02096-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-021-02096-3</ArticleId><ArticleId IdType="pmc">PMC7856789</ArticleId><ArticleId IdType="pubmed">33535966</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran V.H., Ha T.M.T., Le P.T.Q., Nguyen V.N., Phan T.N., Paglietti B. Helicobacter pylori 23S rRNA gene mutations associated with clarithromycin resistance in chronic gastritis in Vietnam. J. Infect. Dev. Ctries. 2018;12:526&#x2013;532. doi: 10.3855/jidc.10000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3855/jidc.10000</ArticleId><ArticleId IdType="pubmed">31954001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty V., Lamichhane B., Tay C.Y., Pai G.C., Lingadakai R., Balaraju G., Shetty S., Ballal M., Chua E.G. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients. Gut. Pathog. 2019;11:21. doi: 10.1186/s13099-019-0305-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13099-019-0305-x</ArticleId><ArticleId IdType="pmc">PMC6513510</ArticleId><ArticleId IdType="pubmed">31110563</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Gasca M., Pe&#xf1;a J., Garc&#xed;a-Amado M.A., Michelangeli F., Contreras M. Point mutations at gyrA and gyrB genes of levofloxacin-resistant Helicobacter pylori isolates in the esophageal mucosa from a Venezuelan population. Am. J. Trop. Med. Hyg. 2018;98:1051&#x2013;1055. doi: 10.4269/ajtmh.17-0478.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.17-0478</ArticleId><ArticleId IdType="pmc">PMC5928819</ArticleId><ArticleId IdType="pubmed">29405113</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimbara E., Noguchi N., Kawai T., Sasatsu M. Fluoroquinolone resistance in Helicobacter pylori: Role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB. Helicobacter. 2012;17:36&#x2013;42. doi: 10.1111/j.1523-5378.2011.00912.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-5378.2011.00912.x</ArticleId><ArticleId IdType="pubmed">22221614</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandan V., Logan S.M., Harrison B.A., Vinogradov E., Aubry A., Stupak J., Li J., Altman E. Characterization of a waaF mutant of Helicobacter pylori strain 26,695 provides evidence that an extended lipopolysaccharide structure has a limited role in the invasion of gastric cancer cells. Biochem. Cell Biol. 2007;85:582&#x2013;590. doi: 10.1139/O07-056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/O07-056</ArticleId><ArticleId IdType="pubmed">17901900</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Zhang X., Wen Y., Chen H., She F. A newly discovered drug resistance gene rfaF in Helicobacter pylori. Infect. Drug Resist. 2019;12:3507&#x2013;3514. doi: 10.2147/IDR.S231152.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S231152</ArticleId><ArticleId IdType="pmc">PMC6858805</ArticleId><ArticleId IdType="pubmed">31814739</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi S.J., Sheikh A.F., Goodarzi H., Yadyad M.J., Seyedian S.S., Aslani S., Assarzadegan M.A. Genetic basis for metronidazole and clarithromycin resistance in Helicobacter pylori strains isolated from patients with gastroduodenal disorders. Infect. Drug Resist. 2019;12:535&#x2013;543. doi: 10.2147/IDR.S192942.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IDR.S192942</ArticleId><ArticleId IdType="pmc">PMC6404679</ArticleId><ArticleId IdType="pubmed">30881059</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks P.J., Edwards D.I. Metronidazole resistance in Helicobacter pylori. Int. J. Antimicrob. Agents. 2002;19:1&#x2013;7. doi: 10.1016/S0924-8579(01)00468-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0924-8579(01)00468-X</ArticleId><ArticleId IdType="pubmed">11814762</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-J&#xfa;lvez M., Rojas A.L., Olekhnovich I., Espinosa Angarica V., Hoffman P.S., Sancho J. Structure of RdxA&#x2014;An oxygen-insensitive nitroreductase essential for metronidazole activation in Helicobacter pylori. Febs. J. 2012;279:4306&#x2013;4317. doi: 10.1111/febs.12020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.12020</ArticleId><ArticleId IdType="pmc">PMC3504637</ArticleId><ArticleId IdType="pubmed">23039228</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.Y., Joo Y.M., Lee H.S., Chung I.S., Yoo Y.J., Merrell D.S., Cha J.H. Genetic analysis of Helicobacter pylori clinical isolates suggests resistance to metronidazole can occur without the loss of functional rdxA. J. Antibiot. 2009;62:43&#x2013;50. doi: 10.1038/ja.2008.6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ja.2008.6</ArticleId><ArticleId IdType="pubmed">19132060</ArticleId></ArticleIdList></Reference><Reference><Citation>Carothers J.J., Bruce M.G., Hennessy T.W., Bensler M., Morris J.M., Reasonover A.L., Hurlburt D.A., Parkinson A.J., Coleman J.M., McMahon B.J. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin. Infect. Dis. 2007;44:e5&#x2013;e8. doi: 10.1086/510074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/510074</ArticleId><ArticleId IdType="pubmed">17173210</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty V., Lingadakai R., Pai G.C., Ballal M. Profile of Helicobacter pylori cagA &amp;vacA genotypes and its association with the spectrum of gastroduodenal disease. Indian. J. Med. Microbiol. 2021;39:495&#x2013;499. doi: 10.1016/j.ijmmb.2021.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmmb.2021.06.001</ArticleId><ArticleId IdType="pubmed">34172322</ArticleId></ArticleIdList></Reference><Reference><Citation>Taneike I., Nami A., O&#x2019;Connor A., Fitzgerald N., Murphy P., Qasim A., O&#x2019;Connor H., O&#x2019;Morain C. Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: Is there any relationship between resistance to metronidazole and cagA status? Aliment Pharmacol. Ther. 2009;30:784&#x2013;790. doi: 10.1111/j.1365-2036.2009.04095.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2009.04095.x</ArticleId><ArticleId IdType="pubmed">19604178</ArticleId></ArticleIdList></Reference><Reference><Citation>Junaid M., Linn A.K., Javadi M.B., Al-Gubare S., Ali N., Katzenmeier G. Vacuolating cytotoxin A (VacA)&#x2014;A multi-talented pore-forming toxin from Helicobacter pylori. Toxicon. 2016;118:27&#x2013;35. doi: 10.1016/j.toxicon.2016.04.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.toxicon.2016.04.037</ArticleId><ArticleId IdType="pubmed">27105670</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyanova L., Markovska R., Yordanov D., Gergova G., Mitov I. Clarithromycin resistance mutations in Helicobacter pylori in association with virulence factors and antibiotic susceptibility of the strains. Microb. Drug Resist. 2016;22:227&#x2013;232. doi: 10.1089/mdr.2015.0199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/mdr.2015.0199</ArticleId><ArticleId IdType="pubmed">26618567</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabiber H., Selimoglu M.A., Otlu B., Yildirim O., Ozer A. Virulence factors and antibiotic resistance in children with Helicobacter pylori gastritis. J. Pediatr. Gastroenterol. Nutr. 2014;58:608&#x2013;612. doi: 10.1097/MPG.0000000000000273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000000273</ArticleId><ArticleId IdType="pubmed">24792628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Guo Q., Yuan Y., Gong Y. The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC Microbiol. 2019;19:152. doi: 10.1186/s12866-019-1517-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12866-019-1517-4</ArticleId><ArticleId IdType="pmc">PMC6611032</ArticleId><ArticleId IdType="pubmed">31272365</ArticleId></ArticleIdList></Reference><Reference><Citation>Guevara B., Cogdill A.G. Helicobacter pylori: A review of current diagnostic and management strategies. Dig. Dis. Sci. 2020;65:1917&#x2013;1931. doi: 10.1007/s10620-020-06193-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-020-06193-7</ArticleId><ArticleId IdType="pubmed">32170476</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham D.Y., Canaan Y., Maher J., Wiener G., Hulten K.G., Kalfus I.N. Rifabutin-based triple therapy (RHB-105) for Helicobacter pylori eradication: A double-blind, randomized, controlled trial. Ann. Intern. Med. 2020;172:795&#x2013;802. doi: 10.7326/M19-3734.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M19-3734</ArticleId><ArticleId IdType="pubmed">32365359</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishizawa T., Suzuki H., Matsuzaki J., Muraoka H., Tsugawa H., Hirata K., Hibi T. Helicobacter pylori resistance to rifabutin in the last 7 years. Antimicrob. Agents Chemother. 2011;55:5374&#x2013;5375. doi: 10.1128/AAC.05437-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05437-11</ArticleId><ArticleId IdType="pmc">PMC3195021</ArticleId><ArticleId IdType="pubmed">21896915</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribaldone D.G., Fagoonee S., Astegiano M., Durazzo M., Morgando A., Sprujevnik T., Giordanino C., Baronio M., De Angelis C., Saracco G.M., et al. Rifabutin-based rescue therapy for Helicobacter pylori eradication: A long-term prospective study in a large cohort of difficult-to-treat patients. J. Clin. Med. 2019;8:199. doi: 10.3390/jcm8020199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm8020199</ArticleId><ArticleId IdType="pmc">PMC6406425</ArticleId><ArticleId IdType="pubmed">30736338</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu P.P., Rayapudi K., Pacana T., Shah N.J., Krishnaswamy N., Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am. J. Gastroenterol. 2011;106:1970&#x2013;1975. doi: 10.1038/ajg.2011.306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2011.306</ArticleId><ArticleId IdType="pmc">PMC3209586</ArticleId><ArticleId IdType="pubmed">21989146</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;graud F., Occhialini A., Rossignol J.F. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob. Agents Chemother. 1998;42:2836&#x2013;2840. doi: 10.1128/AAC.42.11.2836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.42.11.2836</ArticleId><ArticleId IdType="pmc">PMC105952</ArticleId><ArticleId IdType="pubmed">9797212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisson G., Goodwin A., Raudonikiene A., Hughes N.J., Mukhopadhyay A.K., Berg D.E., Hoffman P.S. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob. Agents Chemother. 2002;46:2116&#x2013;2123. doi: 10.1128/AAC.46.7.2116-2123.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.46.7.2116-2123.2002</ArticleId><ArticleId IdType="pmc">PMC127316</ArticleId><ArticleId IdType="pubmed">12069963</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttner Y., Windsor H.M., Viiala C.H., Dusci L., Marshall B.J. Nitazoxanide in treatment of Helicobacter pylori: A clinical and in vitro study. Antimicrob. Agents Chemother. 2003;47:3780&#x2013;3783. doi: 10.1128/AAC.47.12.3780-3783.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.12.3780-3783.2003</ArticleId><ArticleId IdType="pmc">PMC296191</ArticleId><ArticleId IdType="pubmed">14638482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.W., Hu W.L., Cai Y., Zheng W.F., Du Q., Kim J.J., Kao J.Y., Dai N., Si J.M. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J. Gastroenterol. 2018;24:4596&#x2013;4605. doi: 10.3748/wjg.v24.i40.4596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v24.i40.4596</ArticleId><ArticleId IdType="pmc">PMC6209572</ArticleId><ArticleId IdType="pubmed">30386109</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham D.Y., Dore M.P. Update on the use of vonoprazan: A competitive acid blocker. Gastroenterology. 2018;154:462&#x2013;466. doi: 10.1053/j.gastro.2018.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.01.018</ArticleId><ArticleId IdType="pubmed">29337157</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanabe H., Ando K., Sato K., Ito T., Goto M., Sato T., Fujinaga A., Kawamoto T., Utsumi T., Yanagawa N., et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: A multicenter study and a review of the literature. Dig. Dis. Sci. 2017;62:3069&#x2013;3076. doi: 10.1007/s10620-017-4664-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-017-4664-1</ArticleId><ArticleId IdType="pubmed">28664410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.W., Kim N., Nam R.H., Lee S.M., Kwon Y.H., Sohn S.D., Kim J.M., Lee D.H., Jung H.C. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter. 2019;24:e12561. doi: 10.1111/hel.12561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12561</ArticleId><ArticleId IdType="pubmed">30632237</ArticleId></ArticleIdList></Reference><Reference><Citation>Klesiewicz K., Nowak P., Karczewska E., Skiba I., Wojtas-Bonior I., Sito E., Budak A. PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains. Acta Biochim. Pol. 2014;61:311&#x2013;315. doi: 10.18388/abp.2014_1901.</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2014_1901</ArticleId><ArticleId IdType="pubmed">24927236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Talarico S., Yao L., He L., Self S., You Y., Zhang H., Zhang Y., Guo Y., Liu G., et al. Droplet digital PCR-based detection of clarithromycin resistance in Helicobacter pylori isolates reveals frequent heteroresistance. J. Clin. Microbiol. 2018;56:e00019-18. doi: 10.1128/JCM.00019-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00019-18</ArticleId><ArticleId IdType="pmc">PMC6113488</ArticleId><ArticleId IdType="pubmed">29925646</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.Y., Shen W.X., Chen C.F., Sheng H.H., Cheng H., Li J., Hu F., Lu D.R., Gao H.J. Detection of the clarithromycin resistance of Helicobacter pylori in gastric mucosa by the amplification refractory mutation system combined with quantitative real-time PCR. Cancer Med. 2019;8:1633&#x2013;1640. doi: 10.1002/cam4.1986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.1986</ArticleId><ArticleId IdType="pmc">PMC6488203</ArticleId><ArticleId IdType="pubmed">30864275</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Correa J.J., Urruzuno P., Barrio J., Martinez M.J., Agudo S., Somodevilla A., Llorca L., Alarc&#xf3;n T. Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. Diagn. Microbiol. Infect. Dis. 2017;87:150&#x2013;153. doi: 10.1016/j.diagmicrobio.2016.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2016.03.001</ArticleId><ArticleId IdType="pubmed">27863951</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastukh N., Binyamin D., On A., Paritsky M., Peretz A. GenoType&#xae; HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. Helicobacter. 2017;22:e12447. doi: 10.1111/hel.12447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12447</ArticleId><ArticleId IdType="pubmed">29058343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon Y.H., Jeon S.W., Nam S.Y., Lee H.S., Park J.H. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019;24:e12585. doi: 10.1111/hel.12585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12585</ArticleId><ArticleId IdType="pubmed">30969459</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou J.M., Chen C.C., Chang C.Y., Chen M.J., Fang Y.J., Lee J.Y., Chen C.C., Hsu S.J., Hsu Y.C., Tseng C.H., et al. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial. J. Antimicrob. Chemother. 2013;68:450&#x2013;456. doi: 10.1093/jac/dks407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dks407</ArticleId><ArticleId IdType="pubmed">23099849</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano M., Marmo R., Cuomo A., De Simone T., Mucherino C., Iovene M.R., Montella F., Tufano M.A., Del Vecchio Blanco C., Nardone G. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin. Gastroenterol. Hepatol. 2003;1:273&#x2013;278. doi: 10.1016/S1542-3565(03)00131-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1542-3565(03)00131-9</ArticleId><ArticleId IdType="pubmed">15017668</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman E., Saracino I., Fiorini G., Clark C., Slepnev V., Patel D., Gomez C., Ponaka R., Elagin V., Vaira D. A novel stool pcr test for Helicobacter pylori may predict clarithromycin resistance and eradication of infection at a high rate. J. Clin. Microbiol. 2017;55:2400&#x2013;2405. doi: 10.1128/JCM.00506-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00506-17</ArticleId><ArticleId IdType="pmc">PMC5527417</ArticleId><ArticleId IdType="pubmed">28515219</ArticleId></ArticleIdList></Reference><Reference><Citation>Roszczenko-Jasi&#x144;ska P., Wojty&#x15b; M.I., Jagusztyn-Krynicka E.K. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl. Microbiol. Biotechnol. 2020;104:9891&#x2013;9905. doi: 10.1007/s00253-020-10945-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00253-020-10945-w</ArticleId><ArticleId IdType="pmc">PMC7666284</ArticleId><ArticleId IdType="pubmed">33052519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J., Zhang C., Liu Y., Huang Y., Bai Y., Hang X., Zeng L., Zhu D., Bi H. Armeniaspirol A: A novel anti-Helicobacter pylori agent. Microb. Biotechnol. 2021;15:442&#x2013;454. doi: 10.1111/1751-7915.13807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1751-7915.13807</ArticleId><ArticleId IdType="pmc">PMC8867979</ArticleId><ArticleId IdType="pubmed">33780131</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu C., Xie F., Hoffmann J., Wang Q., Bauer A., Br&#xf6;nstrup M., Mahmud T., M&#xfc;ller R. Armeniaspirol antibiotic biosynthesis: Chlorination and oxidative dechlorination steps affording Spiro[4.4]non-8-ene. Chembiochem. 2019;20:764&#x2013;769. doi: 10.1002/cbic.201800791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbic.201800791</ArticleId><ArticleId IdType="pubmed">30556942</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo P., Huang Y., Hang X., Tong Q., Zeng L., Jia J., Zhang G., Bi H. Dihydrotanshinone I is effective against drug-resistant Helicobacter pylori in vitro and in vivo. Antimicrob. Agents Chemother. 2021;65:e01921-20. doi: 10.1128/AAC.01921-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01921-20</ArticleId><ArticleId IdType="pmc">PMC8092497</ArticleId><ArticleId IdType="pubmed">33318002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez A., Salillas S., Vel&#xe1;zquez-Campoy A., Espinosa Angarica V., Fillat M.F., Sancho J., Lanas &#xc1;. Identifying potential novel drugs against Helicobacter pylori by targeting the essential response regulator HsrA. Sci. Rep. 2019;9:11294. doi: 10.1038/s41598-019-47746-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47746-9</ArticleId><ArticleId IdType="pmc">PMC6683298</ArticleId><ArticleId IdType="pubmed">31383920</ArticleId></ArticleIdList></Reference><Reference><Citation>Olekhnovich I.N., Vitko S., Valliere M., Hoffman P.S. Response to metronidazole and oxidative stress is mediated through homeostatic regulator HsrA (HP1043) in Helicobacter pylori. J. Bacteriol. 2014;196:729&#x2013;739. doi: 10.1128/JB.01047-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JB.01047-13</ArticleId><ArticleId IdType="pmc">PMC3911170</ArticleId><ArticleId IdType="pubmed">24296668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon D.H., Lee M., Kim J.J., Kim J.G., El-Zaatari F.A., Osato M.S., Graham D.Y. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: Prevalence and role of genes involved in metronidazole resistance. Antimicrob. Agents Chemother. 2001;45:306&#x2013;308. doi: 10.1128/AAC.45.1.306-308.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.45.1.306-308.2001</ArticleId><ArticleId IdType="pmc">PMC90279</ArticleId><ArticleId IdType="pubmed">11120984</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Advancing Translational Sciences . Inxight Drugs. National Center for Advancing Translational Sciences; Bethesda, MD, USA: 2013.</Citation></Reference><Reference><Citation>Wang J., Cao Y., He W., Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine. 2021;100:e28323. doi: 10.1097/MD.0000000000028323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000028323</ArticleId><ArticleId IdType="pmc">PMC8701960</ArticleId><ArticleId IdType="pubmed">34941132</ArticleId></ArticleIdList></Reference><Reference><Citation>Salillas S., Al&#xed;as M., Michel V., Mah&#xed;a A., Luc&#xed;a A., Rodrigues L., Bueno J., Galano-Frutos J.J., De Reuse H., Vel&#xe1;zquez-Campoy A., et al. Design, synthesis, and efficacy testing of nitroethylene- and 7-nitrobenzoxadiazol-based flavodoxin inhibitors against Helicobacter pylori drug-resistant clinical strains and in Helicobacter pylori-infected mice. J. Med. Chem. 2019;62:6102&#x2013;6115. doi: 10.1021/acs.jmedchem.9b00355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b00355</ArticleId><ArticleId IdType="pubmed">31244111</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi J., Xu C., Liu X., Wu H., Xie X., Liu P., Li H., Zhang G., Xu M., Li C., et al. A comparison of doxycycline and amoxicillin containing quadruple eradication therapy for treating helicobacter pylori-infected duodenal ulcers: A multicenter, opened, randomized controlled trial in china. Pathogens. 2022;11:1549. doi: 10.3390/pathogens11121549.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11121549</ArticleId><ArticleId IdType="pmc">PMC9783029</ArticleId><ArticleId IdType="pubmed">36558883</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhalabi M., Alassi M.W., Alaa Eddin K., Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: A prospective single-center randomized controlled trial. BMC Infect. Dis. 2021;21:642. doi: 10.1186/s12879-021-06356-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-06356-5</ArticleId><ArticleId IdType="pmc">PMC8254989</ArticleId><ArticleId IdType="pubmed">34218802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata S.K., Godoy A.P., da Silva Patricio F.R., Kawakami E. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J. Pediatr. Gastroenterol. Nutr. 2013;56:645&#x2013;648. doi: 10.1097/MPG.0b013e31828b3669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0b013e31828b3669</ArticleId><ArticleId IdType="pubmed">23403439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu P.I., Tsay F.W., Kao J.Y., Peng N.J., Chen Y.H., Tang S.Y., Kuo C.H., Kao S.S., Wang H.M., Wu I.T., et al. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter. 2021;26:e12840. doi: 10.1111/hel.12840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12840</ArticleId><ArticleId IdType="pubmed">34390083</ArticleId></ArticleIdList></Reference><Reference><Citation>Siavoshi F., Saniee P., Latifi-Navid S., Massarrat S., Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies. Arch. Iran Med. 2010;13:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">20433221</ArticleId></ArticleIdList></Reference><Reference><Citation>Miri A.H., Kamankesh M., Llopis-Lorente A., Liu C., Wacker M.G., Haririan I., Asadzadeh Aghdaei H., Hamblin M.R., Yadegar A., Rad-Malekshahi M., et al. The potential use of antibiotics against Helicobacter pylori infection: Biopharmaceutical implications. Front. Pharmacol. 2022;13:917184. doi: 10.3389/fphar.2022.917184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.917184</ArticleId><ArticleId IdType="pmc">PMC9271669</ArticleId><ArticleId IdType="pubmed">35833028</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y.F., Zhou M.L., Wang Y.P., Zhu Y. Mechanism of dihydrotanshinone I in the treatment of helicobacter pylori infection based on network pharmacology and molecular docking technology. Med. Data Min. 2022;5:9. doi: 10.53388/MDM20220520009.</Citation><ArticleIdList><ArticleId IdType="doi">10.53388/MDM20220520009</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero M., Freire J., Pastene E., Garc&#xed;a A., Aranda M., Gonz&#xe1;lez C. Propolis polyphenolic compounds affect the viability and structure of Helicobacter pylori in vitro. Rev. Bras. Farmacogn. 2019;29:325&#x2013;332. doi: 10.1016/j.bjp.2019.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bjp.2019.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Widelski J., Oki&#x144;czyc P., Su&#x15b;niak K., Malm A., Bozhadze A., Jokhadze M., Korona-G&#x142;owniak I. Correlation between chemical profile of Georgian propolis extracts and their activity against Helicobacter pylori. Molecules. 2023;28:1374. doi: 10.3390/molecules28031374.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28031374</ArticleId><ArticleId IdType="pmc">PMC9921474</ArticleId><ArticleId IdType="pubmed">36771040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi M., Mishra M., Pandey A., Gupta J., Pandey J., Gupta S., Malik M.Z., Somvanshi P., Chaturvedi R. Oxidative products of curcumin rather than curcumin bind to Helicobacter Pylori virulence factor VacA and are required to inhibit Its vacuolation activity. Molecules. 2022;27:6727. doi: 10.3390/molecules27196727.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27196727</ArticleId><ArticleId IdType="pmc">PMC9572645</ArticleId><ArticleId IdType="pubmed">36235264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray A.K., Luis P.B., Mishra S.K., Barry D.P., Asim M., Pandey A., Chaturvedi M., Gupta J., Gupta S., Mahant S., et al. Curcumin oxidation Is required for inhibition of Helicobacter pylori growth, translocation and phosphorylation of Cag A. Front. Cell Infect. Microbiol. 2021;11:765842. doi: 10.3389/fcimb.2021.765842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.765842</ArticleId><ArticleId IdType="pmc">PMC8740292</ArticleId><ArticleId IdType="pubmed">35004346</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar A., De R., Mukhopadhyay A.K. Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases. World. J. Gastroenterol. 2016;22:2736&#x2013;2748. doi: 10.3748/wjg.v22.i9.2736.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i9.2736</ArticleId><ArticleId IdType="pmc">PMC4777996</ArticleId><ArticleId IdType="pubmed">26973412</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwahori A., Hirota Y., Sampe R., Miyano S., Takahashi N., Sasatsu M., Kondo I., Numao N. On the antibacterial activity of normal and reversed magainin 2 analogs against Helicobacter pylori. Biol. Pharm. Bull. 1997;20:805&#x2013;808. doi: 10.1248/bpb.20.805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.20.805</ArticleId><ArticleId IdType="pubmed">9255424</ArticleId></ArticleIdList></Reference><Reference><Citation>Neshani A., Zare H., Akbari Eidgahi M.R., Hooshyar Chichaklu A., Movaqar A., Ghazvini K. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2019;24:e12555. doi: 10.1111/hel.12555.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12555</ArticleId><ArticleId IdType="pubmed">30440101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamoorthy A., Thennarasu S., Lee D.K., Tan A., Maloy L. Solid-state NMR investigation of the membrane-disrupting mechanism of antimicrobial peptides MSI-78 and MSI-594 derived from magainin 2 and melittin. Biophys. J. 2006;91:206&#x2013;216. doi: 10.1529/biophysj.105.073890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.105.073890</ArticleId><ArticleId IdType="pmc">PMC1479060</ArticleId><ArticleId IdType="pubmed">16603496</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayana J.L., Huang H.N., Wu C.J., Chen J.Y. Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: In vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model. Oncotarget. 2015;6:12936&#x2013;12954. doi: 10.18632/oncotarget.4101.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.4101</ArticleId><ArticleId IdType="pmc">PMC4536990</ArticleId><ArticleId IdType="pubmed">26002554</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.Y., Lin W.J., Wu J.L., Her G.M., Hui C.F. Epinecidin-1 peptide induces apoptosis which enhances antitumor effects in human leukemia U937 cells. Peptides. 2009;30:2365&#x2013;2373. doi: 10.1016/j.peptides.2009.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2009.08.019</ArticleId><ArticleId IdType="pubmed">19720101</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Wu W.K., Gallo R.L., Fang E.F., Hu W., Ling T.K., Shen J., Chan R.L., Lu L., Luo X.M., et al. Critical role of antimicrobial peptide cathelicidin for controlling Helicobacter pylori survival and infection. J. Immunol. 2016;196:1799&#x2013;1809. doi: 10.4049/jimmunol.1500021.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1500021</ArticleId><ArticleId IdType="pubmed">26800870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J. Clin. Investig. 1991;88:93&#x2013;100. doi: 10.1172/JCI115310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI115310</ArticleId><ArticleId IdType="pmc">PMC296007</ArticleId><ArticleId IdType="pubmed">2056135</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahl H.G., Pag U., Bonness S., Wagner S., Antcheva N., Tossi A. Mammalian defensins: Structures and mechanism of antibiotic activity. J. Leukoc. Biol. 2005;77:466&#x2013;475. doi: 10.1189/jlb.0804452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0804452</ArticleId><ArticleId IdType="pubmed">15582982</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xe9;n&#xe9; N., Bonnaf&#xe9; E., Berger F., Rifflet A., Guilhaudis L., S&#xe9;galas-Milazzo I., Pipy B., Coste A., Leprince J., Treilhou M. Biochemical and biophysical combined study of bicarinalin, an ant venom antimicrobial peptide. Peptides. 2016;79:103&#x2013;113. doi: 10.1016/j.peptides.2016.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2016.04.001</ArticleId><ArticleId IdType="pubmed">27058430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Li Y., Li J., Xu X., Lai R., Zou Q. An antimicrobial peptide with antimicrobial activity against Helicobacter pylori. Peptides. 2007;28:1527&#x2013;1531. doi: 10.1016/j.peptides.2007.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2007.07.007</ArticleId><ArticleId IdType="pubmed">17698252</ArticleId></ArticleIdList></Reference><Reference><Citation>Owolabi B.O., Musale V., Ojo O.O., Moffett R.C., McGahon M.K., Curtis T.M., Conlon J.M., Flatt P.R., Abdel-Wahab Y.H.A. Actions of PGLa-AM1 and its [A14K] and [A20K] analogues and their therapeutic potential as anti-diabetic agents. Biochimie. 2017;138:1&#x2013;12. doi: 10.1016/j.biochi.2017.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biochi.2017.04.004</ArticleId><ArticleId IdType="pubmed">28392407</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu S.T., Breukink E., Tischenko E., Lutters M.A., de Kruijff B., Kaptein R., Bonvin A.M., van Nuland N.A. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Nat. Struct. Mol. Biol. 2004;11:963&#x2013;967. doi: 10.1038/nsmb830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb830</ArticleId><ArticleId IdType="pubmed">15361862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Li X., Wang Z. APD3: The antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 2016;44:D1087&#x2013;D1093. doi: 10.1093/nar/gkv1278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkv1278</ArticleId><ArticleId IdType="pmc">PMC4702905</ArticleId><ArticleId IdType="pubmed">26602694</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatcher H., Planalp R., Cho J., Torti F.M., Torti S.V. Curcumin: From ancient medicine to current clinical trials. Cell Mol. Life Sci. 2008;65:1631&#x2013;1652. doi: 10.1007/s00018-008-7452-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-008-7452-4</ArticleId><ArticleId IdType="pmc">PMC4686230</ArticleId><ArticleId IdType="pubmed">18324353</ArticleId></ArticleIdList></Reference><Reference><Citation>De R., Kundu P., Swarnakar S., Ramamurthy T., Chowdhury A., Nair G.B., Mukhopadhyay A.K. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob. Agents Chemother. 2009;53:1592&#x2013;1597. doi: 10.1128/AAC.01242-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01242-08</ArticleId><ArticleId IdType="pmc">PMC2663130</ArticleId><ArticleId IdType="pubmed">19204190</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi-Kanemitsu A., Knight C.T., Hatakeyama M. Molecular anatomy and pathogenic actions of Helicobacter pylori CagA that underpin gastric carcinogenesis. Cell. Mol. Immunol. 2020;17:50&#x2013;63. doi: 10.1038/s41423-019-0339-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-019-0339-5</ArticleId><ArticleId IdType="pmc">PMC6952403</ArticleId><ArticleId IdType="pubmed">31804619</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava A.K., Tewari M., Shukla H.S., Roy B.K. In silico profiling of the potentiality of curcumin and conventional drugs for CagA oncoprotein inactivation. Arch. Pharm. 2015;348:548&#x2013;555. doi: 10.1002/ardp.201400438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ardp.201400438</ArticleId><ArticleId IdType="pubmed">25996140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson K.M., Dahlin J.L., Bisson J., Graham J., Pauli G.F., Walters M.A. Curcumin may (not) defy science. ACS Med. Chem. Lett. 2017;8:467&#x2013;470. doi: 10.1021/acsmedchemlett.7b00139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.7b00139</ArticleId><ArticleId IdType="pmc">PMC5430405</ArticleId><ArticleId IdType="pubmed">28523093</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Li W., Hu G., Sun H., Kong Q. Bioactivities of EF24, a novel curcumin analog: A review. Front. Oncol. 2018;8:614. doi: 10.3389/fonc.2018.00614.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00614</ArticleId><ArticleId IdType="pmc">PMC6297553</ArticleId><ArticleId IdType="pubmed">30619754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.L., Jiang A.M., Ma Z.Y., Li X.B., Xiong Y.Y., Dou J.F., Wang J.F. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo. Molecules. 2015;20:3972&#x2013;3985. doi: 10.3390/molecules20033972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules20033972</ArticleId><ArticleId IdType="pmc">PMC6272436</ArticleId><ArticleId IdType="pubmed">25738539</ArticleId></ArticleIdList></Reference><Reference><Citation>Homan M., Orel R. Are probiotics useful in Helicobacter pylori eradication? World J. Gastroenterol. 2015;21:10644&#x2013;10653. doi: 10.3748/wjg.v21.i37.10644.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i37.10644</ArticleId><ArticleId IdType="pmc">PMC4588086</ArticleId><ArticleId IdType="pubmed">26457024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji J., Yang H. Using probiotics as supplementation for Helicobacter pylori antibiotic therapy. Int. J. Mol. Sci. 2020;21:1136. doi: 10.3390/ijms21031136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21031136</ArticleId><ArticleId IdType="pmc">PMC7037652</ArticleId><ArticleId IdType="pubmed">32046317</ArticleId></ArticleIdList></Reference><Reference><Citation>Francavilla R., Polimeno L., Demichina A., Maurogiovanni G., Principi B., Scaccianoce G., Ierardi E., Russo F., Riezzo G., Di Leo A., et al. Lactobacillus reuteri strain combination in Helicobacter pylori infection: A randomized, double-blind, placebo-controlled study. J. Clin. Gastroenterol. 2014;48:407&#x2013;413. doi: 10.1097/MCG.0000000000000007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000007</ArticleId><ArticleId IdType="pubmed">24296423</ArticleId></ArticleIdList></Reference><Reference><Citation>Urrutia-Baca V.H., Escamilla-Garc&#xed;a E., de la Garza-Ramos M.A., Tamez-Guerra P., Gomez-Flores R., Urbina-R&#xed;os C.S. In vitro antimicrobial activity and downregulation of virulence gene expression on Helicobacter pylori by reuterin. Probiotics Antimicrob. Proteins. 2018;10:168&#x2013;175. doi: 10.1007/s12602-017-9342-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-017-9342-2</ArticleId><ArticleId IdType="pubmed">29103130</ArticleId></ArticleIdList></Reference><Reference><Citation>Vale F.F., Oleastro M. Overview of the phytomedicine approaches against Helicobacter pylori. World J. Gastroenterol. 2014;20:5594&#x2013;5609. doi: 10.3748/wjg.v20.i19.5594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i19.5594</ArticleId><ArticleId IdType="pmc">PMC4024768</ArticleId><ArticleId IdType="pubmed">24914319</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Li X., Tan Z. An overview of traditional Chinese medicine therapy for Helicobacter pylori-related gastritis. Helicobacter. 2021;26:e12799. doi: 10.1111/hel.12799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hel.12799</ArticleId><ArticleId IdType="pubmed">33765344</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi B., Sharopov F., Martorell M., Rajkovic J., Ademiluyi A.O., Sharifi-Rad M., Fokou P.V.T., Martins N., Iriti M., Sharifi-Rad J. Phytochemicals in Helicobacter pylori infections: What are we doing now? Int. J. Mol. Sci. 2018;19:2361. doi: 10.3390/ijms19082361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19082361</ArticleId><ArticleId IdType="pmc">PMC6121492</ArticleId><ArticleId IdType="pubmed">30103451</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C., Liu L., Zhu S., Wei M. Effectiveness and safety of Chinese medicine combined with omeprazole in the treatment of gastric ulcer: A protocol for systematic review and meta-analysis. Medicine. 2021;100:e25744. doi: 10.1097/MD.0000000000025744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000025744</ArticleId><ArticleId IdType="pmc">PMC8084060</ArticleId><ArticleId IdType="pubmed">33907169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye H., Shi Z.M., Chen Y., Yu J., Zhang X.Z. Innovative perspectives of integrated Chinese medicine on H. pylori. Chin. J. Integr. Med. 2018;24:873&#x2013;880. doi: 10.1007/s11655-017-2934-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11655-017-2934-6</ArticleId><ArticleId IdType="pubmed">29882207</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma F., Chen Y., Li J., Qing H.P., Wang J.D., Zhang Y.L., Long B.G., Bai Y. Screening test for anti-Helicobacter pylori activity of traditional Chinese herbal medicines. World. J. Gastroenterol. 2010;16:5629&#x2013;5634. doi: 10.3748/wjg.v16.i44.5629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i44.5629</ArticleId><ArticleId IdType="pmc">PMC2992683</ArticleId><ArticleId IdType="pubmed">21105198</ArticleId></ArticleIdList></Reference><Reference><Citation>Argueta E.A., Ho J.J.C., Elfanagely Y., D&#x2019;Agata E., Moss S.F. Clinical implication of drug resistance for H. pylori management. Antibiotics. 2022;11:1684. doi: 10.3390/antibiotics11121684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11121684</ArticleId><ArticleId IdType="pmc">PMC9774604</ArticleId><ArticleId IdType="pubmed">36551341</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;graud F. H pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut. 2004;53:1374&#x2013;1384. doi: 10.1136/gut.2003.022111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.022111</ArticleId><ArticleId IdType="pmc">PMC1774187</ArticleId><ArticleId IdType="pubmed">15306603</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizwan M., Fatima N., Alvi A. Epidemiology and pattern of antibiotic resistance in Helicobacter pylori: Scenario from Saudi Arabia. Saudi J. Gastroenterol. 2014;20:212&#x2013;218. doi: 10.4103/1319-3767.136935.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1319-3767.136935</ArticleId><ArticleId IdType="pmc">PMC4131303</ArticleId><ArticleId IdType="pubmed">25038206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestegard O., Moayeri B., Halvorsen F.A., T&#xf8;nnesen T., S&#xf8;rbye S.W., Paulssen E., Johnsen K.M., Goll R., Florholmen J.R., Melby K.K. Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS ONE. 2022;17:e0265322. doi: 10.1371/journal.pone.0265322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0265322</ArticleId><ArticleId IdType="pmc">PMC9020706</ArticleId><ArticleId IdType="pubmed">35442962</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Antimicrobial Resistance. World Health Organization; Geneva, Switzerland: 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>